Bristol-Myers Squibb Company (BMY): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Bristol-Myers Squibb Company ( BMY) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.4%. By the end of trading, Bristol-Myers Squibb Company fell $0.74 (-1.6%) to $46.19 on average volume. Throughout the day, 7,997,790 shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 7,053,300 shares. The stock ranged in price between $45.90-$46.72 after having opened the day at $46.59 as compared to the previous trading day's close of $46.93. Other companies within the Drugs industry that declined today were: Nektar Therapeutics ( NKTR), down 23.9%, Cellular Dynamics International ( ICEL), down 10.7%, TG Therapeutics ( TGTX), down 7.6% and Chembio Diagnostics ( CEMI), down 6.4%.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $77.1 billion and is part of the health care sector. Shares are up 43.7% year to date as of the close of trading on Thursday. Currently there are 7 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 10 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, Cardium Therapeutics ( CXM), up 27.8%, Zalicus ( ZLCS), up 26.8%, Rockwell Medical ( RMTI), up 16.9% and ZIOPHARM Oncology ( ZIOP), up 13.8% , were all gainers within the drugs industry with Valeant Pharmaceuticals International ( VRX) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

Bristol-Myers 'Is Back' and Could Soar Another 14%

Bristol-Myers 'Is Back' and Could Soar Another 14%

These Were the 3 Hottest Stories on Wall Street Thursday

These Were the 3 Hottest Stories on Wall Street Thursday

Rock and Roll: Bristol-Myers Squibb Is Breaking Out

Rock and Roll: Bristol-Myers Squibb Is Breaking Out

Dow Soars Over 250 Points to Post Its Fourth Straight Day of Gains